528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours

MLA

James Spicer, et al. “528 Intratumoural Treatment with LTX-, an Oncolytic Peptide Immunotherapy, in Patients with Advanced Metastatic Disease Induces CD8 Effector Cells and Regression in Some Injected Tumours.” European Journal of Cancer, vol. 51, Sept. 2015, p. S113. EBSCOhost, https://doi.org/10.1016/s0959-8049(16)30329-x.

APA

James Spicer, Jean-François Baurain, A. Saunders, Jalal Vakili, O. Rekdal, Philippe Aftimos, B. Nicolaisen, F. Marjuadi, W.M. Olsen, M. Laruelle, P. Brunsvig, Ahmad Awada, Philippe Barthélémy, & S. Deva. (2015). 528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours. European Journal of Cancer, 51, S113. https://doi.org/10.1016/s0959-8049(16)30329-x

Chicago

James Spicer, Jean-François Baurain, A. Saunders, Jalal Vakili, O. Rekdal, Philippe Aftimos, B. Nicolaisen, et al. 2015. “528 Intratumoural Treatment with LTX-, an Oncolytic Peptide Immunotherapy, in Patients with Advanced Metastatic Disease Induces CD8 Effector Cells and Regression in Some Injected Tumours.” European Journal of Cancer 51 (September): S113. doi:10.1016/s0959-8049(16)30329-x.